The histone methyltransferase enhancer of zeste 2 (EZH2) is an epigenetic modifier frequently overexpressed in many cancer types including prostate cancer and supports cancer cell proliferation and survival22–25. This evidence concerns the gene EZH2 and prostate carcinoma.